Shares of UCB SA (OTCMKTS:UCBJY – Get Free Report) crossed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $96.49 and traded as low as $93.22. UCB shares last traded at $93.50, with a volume of 9,796 shares.
UCB Trading Down 0.6 %
The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. The firm’s fifty day moving average price is $96.48 and its 200 day moving average price is $91.45.
About UCB
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Further Reading
- Five stocks we like better than UCB
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Oracle Announces Game-Changing News for the AI Industry
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Netflix Adds 19 Million Subscribers, Growth Is Far From Over
- Want to Profit on the Downtrend? Downtrends, Explained.
- Tempus AI: A Game-Changer in AI-Powered Healthcare
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
